Genome-wide association analysis of age-at-onset in Alzheimer's disease
暂无分享,去创建一个
O L Lopez | E Feingold | V. Pankratz | O. Lopez | S. DeKosky | M. Carrasquillo | S. Younkin | R. Sweet | M. Kamboh | E. Feingold | F. Demirci | S. Younkin | M. Barmada | R. Minster | R A Sweet | V S Pankratz | A. Saykin | M I Kamboh | S G Younkin | S T DeKosky | O. Lopez | M. Carrasquillo | M M Barmada | M M Carrasquillo | F Y Demirci | R L Minster | A J Saykin | R. Sweet | MM Barmada | FY Demirci | RL Minster | VS Pankratz | M. Barmada | V. Pankratz
[1] E M Wijsman,et al. The number of trait loci in late-onset Alzheimer disease. , 2000, American journal of human genetics.
[2] Michael Weiner,et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort , 2010, NeuroImage.
[3] C. Di Menza,et al. VLDL receptor polymorphism, cognitive impairment, and dementia , 2001, Neurology.
[4] Suzette J. Bielinski,et al. NRXN3 Is a Novel Locus for Waist Circumference: A Genome-Wide Association Study from the CHARGE Consortium , 2009, PLoS genetics.
[5] Sarah E. Brockwell,et al. A comparison of statistical methods for meta‐analysis , 2001, Statistics in medicine.
[6] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[7] Rajesh Pahwa,et al. Age at onset in two common neurodegenerative diseases is genetically controlled. , 2002, American journal of human genetics.
[8] R. Maki,et al. ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family. , 2000, Genomics.
[9] L. Chan,et al. A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins , 2009, Brain Research.
[10] M. Borodovsky,et al. Identification of new human cadherin genes using a combination of protein motif search and gene finding methods. , 2004, Journal of molecular biology.
[11] L. Fratiglioni,et al. Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.
[12] D. Drachman,et al. Apolipoprotein E ε4 allele and the lifetime risk of Alzheimer's disease : what physicians know, and what they should know , 1995 .
[13] Thomas W. Mühleisen,et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.
[14] J. Morris,et al. Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.
[15] V. Pankratz,et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Nature Genetics.
[16] O. Lopez,et al. Replication study of genome‐wide associated SNPs with late‐onset Alzheimer's disease , 2011, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[17] R. Rosenthal,et al. Genomewide suggestive linkage of opioid dependence to chromosome 14q. , 2007, Human molecular genetics.
[18] Christoph Lange,et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.
[19] D. Drachman,et al. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. , 1995, Archives of neurology.
[20] M. McCarthy,et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes , 2008, Nature Genetics.
[21] Vladimir I. Vladimirov,et al. Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics , 2009, Molecular Psychiatry.
[22] Nick C Fox,et al. Common variants in ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease , 2011, Nature Genetics.
[23] Sudha Seshadri,et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.
[24] Jason H. Moore,et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans , 2010, Alzheimer's & Dementia.
[25] S. DeKosky,et al. Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease , 2006, Neurobiology of Aging.
[26] D. G. Clark,et al. Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease , 2011, Nature Genetics.
[27] R. Hamman,et al. The relationship of APOE polymorphism and cholesterol levels in normoglycemic and diabetic subjects in a biethnic population from the San Luis Valley, Colorado. , 1995, Atherosclerosis.
[28] P. Bosco,et al. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. , 2010, Journal of Alzheimer's disease : JAD.
[29] E. Stanley,et al. Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis , 2007, Journal of Cell Science.
[30] A. Hofman,et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.
[31] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.
[32] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[33] Nick C Fox,et al. Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .
[34] P. Bosco,et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.
[35] L. Kiemeney,et al. Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.